Search research articles
Contact Us
Filters
Showing results (1-10 of 59) with videos related to
Page
of 6
Sort By:
Hematology. American Society of Hematology. Education Program
|
December 7, 2019
What to do with minimal residual disease testing in myeloma
Elisabet E Manasanch
Seminars in Oncology
|
January 8, 2017
Recommend maintenance therapy with lenalidomide in multiple myeloma
Elisabet E Manasanch
Best Practice & Research. Clinical Haematology
|
March 7, 2020
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications
Chutima Kunacheewa, Elisabet E Manasanch
Expert Review of Hematology
|
September 22, 2021
The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact
Chutima Kunacheewa, Elisabet E Manasanch
Nature Reviews. Clinical Oncology
|
January 25, 2017
Proteasome inhibitors in cancer therapy
Elisabet E Manasanch, Robert Z Orlowski
Oncotargets and Therapy
|
March 1, 2017
Carfilzomib boosted combination therapy for relapsed multiple myeloma
Raphael E Steiner, Elisabet E Manasanch
Leukemia & Lymphoma
|
October 25, 2022
The role of soluble B cell maturation antigen as a biomarker in multiple myeloma
Mohammed Alomari, Chutima Kunacheewa, Elisabet E Manasanch
Clinical Lymphoma, Myeloma & Leukemia
|
March 12, 2013
Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions
Elisabet E Manasanch, Sigurdur Y Kristinsson, Ola Landgren
The Oncologist
|
March 22, 2015
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials
Mauricio Burotto, Elisabet E Manasanch, Julia Wilkerson, et al.
European Journal of Haematology
|
October 12, 2013
Smoldering multiple myeloma: present position and potential promises
Nishant Tageja, Elisabet E Manasanch, Neha Korde, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 59) with videos related to
Sort By:
Page
of 6
Hematology. American Society of Hematology. Education Program
|
December 7, 2019
What to do with minimal residual disease testing in myeloma
Elisabet E Manasanch
Seminars in Oncology
|
January 8, 2017
Recommend maintenance therapy with lenalidomide in multiple myeloma
Elisabet E Manasanch
Best Practice & Research. Clinical Haematology
|
March 7, 2020
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications
Chutima Kunacheewa, Elisabet E Manasanch
Expert Review of Hematology
|
September 22, 2021
The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact
Chutima Kunacheewa, Elisabet E Manasanch
Nature Reviews. Clinical Oncology
|
January 25, 2017
Proteasome inhibitors in cancer therapy
Elisabet E Manasanch, Robert Z Orlowski
Oncotargets and Therapy
|
March 1, 2017
Carfilzomib boosted combination therapy for relapsed multiple myeloma
Raphael E Steiner, Elisabet E Manasanch
Leukemia & Lymphoma
|
October 25, 2022
The role of soluble B cell maturation antigen as a biomarker in multiple myeloma
Mohammed Alomari, Chutima Kunacheewa, Elisabet E Manasanch
Clinical Lymphoma, Myeloma & Leukemia
|
March 12, 2013
Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions
Elisabet E Manasanch, Sigurdur Y Kristinsson, Ola Landgren
The Oncologist
|
March 22, 2015
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials
Mauricio Burotto, Elisabet E Manasanch, Julia Wilkerson, et al.
European Journal of Haematology
|
October 12, 2013
Smoldering multiple myeloma: present position and potential promises
Nishant Tageja, Elisabet E Manasanch, Neha Korde, et al.
Page
of 6